Lithium and Triiodothyronine Augmentation of Antidepressants

Objective: To evaluate the relative benefits of the combination of lithium and triiodothyronine (T3) in augmentation of antidepressants, compared with either lithium or T3 alone. Methods: We performed a 2-week, randomized, double-blind, placebo-controlled pilot study of the addition of lithium compa...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of psychiatry 2006-10, Vol.51 (12), p.791-793
Main Authors: Joffe, Russell T, Sokolov, Stephen TH, Levitt, Anthony J
Format: Article
Language:English
Subjects:
Adult
Adult and adolescent clinical studies
Antidepressants
Antidepressive Agents - metabolism
Antidepressive Agents - pharmacokinetics
Antidepressive Agents - therapeutic use
Biological and medical sciences
Depression
Depressive Disorder, Major - drug therapy
Double-Blind Method
Drug Administration Schedule
Drug Resistance
Drug Synergism
Drug Therapy, Combination
Female
Humans
Lithium
Lithium Carbonate - metabolism
Lithium Carbonate - pharmacokinetics
Lithium Carbonate - therapeutic use
Male
Medical sciences
Mental disorders
Mood disorders
Neuropharmacology
Pharmacology. Drug treatments
Psychiatry
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Thyroid gland
Triiodothyronine - pharmacology
Triiodothyronine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To evaluate the relative benefits of the combination of lithium and triiodothyronine (T3) in augmentation of antidepressants, compared with either lithium or T3 alone. Methods: We performed a 2-week, randomized, double-blind, placebo-controlled pilot study of the addition of lithium compared with T3 compared with the combination of both in subjects with major depressive disorder who had not responded to an antidepressant. Results: All groups improved significantly over the 2 weeks of treatment, but there were no significant between-group differences. Conclusion: There may be no advantage to a combination of these augmenting agents, although we failed to show separation between active treatments and placebo.
ISSN:0706-7437
1497-0015
DOI:10.1177/070674370605101209